Lyell Immunopharma Inc (LYEL)
2.46
-0.22
(-8.21%)
USD |
NASDAQ |
May 10, 16:00
2.47
+0.01
(+0.41%)
After-Hours: 20:00
Lyell Immunopharma Total Liabilities (Quarterly): 91.06M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 91.06M |
| December 31, 2023 | 95.08M |
| September 30, 2023 | 97.42M |
| June 30, 2023 | 98.50M |
| March 31, 2023 | 96.62M |
| December 31, 2022 | 104.31M |
| September 30, 2022 | 157.24M |
| Date | Value |
|---|---|
| June 30, 2022 | 153.63M |
| March 31, 2022 | 190.85M |
| December 31, 2021 | 197.62M |
| September 30, 2021 | 211.86M |
| June 30, 2021 | 207.91M |
| March 31, 2021 | 200.27M |
| December 31, 2020 | 189.84M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
91.06M
Minimum
Mar 2024
211.86M
Maximum
Sep 2021
149.44M
Average
155.44M
Median
Total Liabilities (Quarterly) Benchmarks
| GlycoMimetics Inc | 6.902M |
| Candel Therapeutics Inc | 28.46M |
| Eliem Therapeutics Inc | 2.87M |
| Entrada Therapeutics Inc | 241.48M |
| NovaBay Pharmaceuticals Inc | 5.72M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 694.22M |
| Shareholders Equity (Quarterly) | 603.16M |
| Current Ratio | 16.51 |